Taurus Asset Management LLC Acquires 1,130 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Taurus Asset Management LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,125 shares of the biopharmaceutical company’s stock after acquiring an additional 1,130 shares during the quarter. Taurus Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,199,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in REGN. Virtu Financial LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth $6,364,000. Morse Asset Management Inc grew its stake in shares of Regeneron Pharmaceuticals by 0.9% in the 3rd quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock worth $5,053,000 after acquiring an additional 43 shares in the last quarter. Anchor Investment Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 212.0% in the 3rd quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock worth $902,000 after acquiring an additional 583 shares in the last quarter. Sculati Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 1.9% in the third quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock valued at $1,970,000 after purchasing an additional 38 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co lifted its position in shares of Regeneron Pharmaceuticals by 19.0% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock valued at $5,575,000 after purchasing an additional 848 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.4 %

REGN stock opened at $554.18 on Friday. The company has a market capitalization of $60.59 billion, a PE ratio of 14.48, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20. The company’s 50 day moving average price is $659.94 and its two-hundred day moving average price is $755.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company earned $11.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Ratings Changes

Several research firms have commented on REGN. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, TD Cowen lowered their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.